You are here

  • Home
  • Archive
  • Volume 6, Issue 7
  • Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study

Article Text

Article menu

Download PDFPDF

XML
Cardiovascular medicine
Research
Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study
  1. T B Dondo1,
  2. M Hall1,
  3. A D Timmis2,
  4. A T Yan3,
  5. P D Batin4,
  6. G Oliver5,
  7. O A Alabas1,
  8. P Norman6,
  9. J E Deanfield7,
  10. K Bloor8,
  11. H Hemingway9,
  12. C P Gale1,10
  1. 1Leeds Institute of Cardiovascular and Metabolic Medicine, Leeds, UK
  2. 2The National Institute for Health Biomedical Research Unit, Barts Health, London, UK
  3. 3Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  4. 4Department of Cardiology, The Mid Yorkshire Hospitals NHS Trust, Wakefield, UK
  5. 5National Health Service cardiac service user, West Yorkshire, UK
  6. 6School of Geography, University of Leeds, Leeds, UK
  7. 7National Institute for Cardiovascular Outcomes Research, University College London, London, UK
  8. 8Department of Health Sciences, University of York, York, UK
  9. 9The Farr Institute, University College London, London, UK
  10. 10York Teaching Hospital NHS Foundation Trust, York, UK
  1. Correspondence to Dr C P Gale; c.p.gale{at}leeds.ac.uk

Abstract

Objectives To investigate geographic variation in guideline-indicated treatments for non-ST-elevation myocardial infarction (NSTEMI) in the English National Health Service (NHS).

Design Cohort study using registry data from the Myocardial Ischaemia National Audit Project.

Setting All Clinical Commissioning Groups (CCGs) (n=211) in the English NHS.

Participants 357 228 patients with NSTEMI between 1 January 2003 and 30 June 2013.

Main outcome measure Proportion of eligible NSTEMI who received all eligible guideline-indicated treatments (optimal care) according to the date of guideline publication.

Results The proportion of NSTEMI who received optimal care was low (48 257/357 228; 13.5%) and varied between CCGs (median 12.8%, IQR 0.7–18.1%). The greatest geographic variation was for aldosterone antagonists (16.7%, 0.0–40.0%) and least for use of an ECG (96.7%, 92.5–98.7%). The highest rates of care were for acute aspirin (median 92.8%, IQR 88.6–97.1%), and aspirin (90.1%, 85.1–93.3%) and statins (86.4%, 82.3–91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, IQR 8.7–16.6%), dietary advice (32.4%, 23.9–41.7%) and the prescription of P2Y12 inhibitors (39.7%, 32.4–46.9%). After adjustment for case mix, nearly all (99.6%) of the variation was due to between-hospital differences (median 64.7%, IQR 57.4–70.0%; between-hospital variance: 1.92, 95% CI 1.51 to 2.44; interclass correlation 0.996, 95% CI 0.976 to 0.999).

Conclusions Across the English NHS, the optimal use of guideline-indicated treatments for NSTEMI was low. Variation in the use of specific treatments for NSTEMI was mostly explained by between-hospital differences in care. Performance-based commissioning may increase the use of NSTEMI treatments and, therefore, reduce premature cardiovascular deaths.

Trial registration number NCT02436187.

  • NSTEMI
  • National Health Service
  • MINAP
  • Geographic variation
  • Clinical Commissioning Groups
  • Inequalities

This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/

https://doi.org/10.1136/bmjopen-2016-011600

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text